Conference Coverage

Conference Coverage

Novel ddPCR assay precisely measures CAR T-cells after infusion

Author:

Sharon Worcester

Publish date: February 22, 2021

The ddPCR assay is particularly useful for assessing whether low CAR T-cell levels on flow cytometry are...

• Read More

Conference Coverage

Steroid complications in GVHD common, boost costs of care

Author:

Neil Osterweil

Publish date: February 19, 2021

Hospitalizations related to infections and other adverse events associated with steroid use carry a high price...

• Read More

Conference Coverage

CAR T-cell products shine in real-world setting, reveal new insights

Author:

Sharon Worcester

Publish date: February 18, 2021

Real-world CAR-T experience provides new insights for predicting outcomes in patients with DLBCL.

• Read More

Conference Coverage

Chronic GVHD therapies offer hope for treating refractory disease

Author:

Neil Osterweil

Publish date: February 17, 2021

Drugs with novel mechanisms of action are currently in clinical trials for chronic graft-versus-host disease....

• Read More

Conference Coverage

Four-item prognostic index predicts survival in adult Burkitt lymphoma

Author:

Neil Osterweil

Publish date: December 16, 2020

Patients with zero of four risk factors on the Burkitt Lymphoma International Prognostic Index had excellent 3-...

• Read More

Conference Coverage

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies

Author:

Walter Alexander

Publish date: December 11, 2020

Once-daily oral DTRM-555 shows encouraging activity in Richter’s transformation and DLBCL.

• Read More

Conference Coverage

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma

Author:

Andrew D. Bowser

Publish date: December 11, 2020

A 74% complete response rate is encouraging in interim analysis of the phase 2 study, but requires further...

• Read More

Conference Coverage

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL

Author:

Neil Osterweil

Publish date: December 10, 2020

The risk of relapse was more than fourfold higher for patients with DLBCL or Burkitt’s lymphoma treated at adult...

• Read More

Conference Coverage

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL

Author:

Andrew D. Bowser

Publish date: December 10, 2020

Durable responses were seen among patients with follicular lymphoma and diffuse large B-cell lymphoma, an...

• Read More

Conference Coverage

Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patients

Author:

Walter Alexander

Publish date: December 6, 2020

After 12 cycles of ibrutinib/venetoclax, patients then randomized to placebo had 1-year disease-free survival of...

• Read More

Pages

• « first
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• last »